News brief­ing: Ovid shows mixed re­sults on epilep­sy pro­gram; Il­i­ad re­ports pos­i­tive whoop­ing cough da­ta

Ovid Ther­a­peu­tics $OVID an­nounced Wednes­day mixed re­sults of a Phase II study in a pro­gram seek­ing to treat rare epilep­sies.

The 20-pa­tient tri­al, which was a sig­nal-find­ing open-la­bel pi­lot study, mea­sured how its com­pound soti­cle­stat could re­duce the av­er­age fre­quen­cy of seizures in pa­tients with CD­KL5 de­fi­cien­cy dis­or­der and Dup15q syn­drome. In the ini­tial 12-week main­te­nance pe­ri­od, pa­tients with CDD saw an av­er­age re­duc­tion of 24%, but those with Dup15q saw an in­creased seizure fre­quen­cy of 12%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER